Mechanism of Aidi injection on hepatocellular carcinoma based on network pharmacology

Objective:To explore the active ingredients and potential mechanism of Aidi injection in the treatment of hepatocellular carcinoma by network pharmacology.Methods:Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and Traditional Chinese Medicines Integrated Database(TCMID)were used to screen the active ingredients of four traditional Chinese medicines of Renshen,Huangqi,Ciwujia,and Banmao and corresponding potential targets.Screening of hepatocellular carcinoma-related targets through the Online Mendelian Inheritance in Man(OMIM)and GeneCards Suite(The Human Gene Database)database platforms.The drug and disease targets are merged to obtain the intersection,and the information is imported into Cytoscape 3.7.2 to construct a network diagram of the active ingredients of Aidi injection and related targets of hepatocellular carcinoma,and the topology analysis is performed.A protein-protein interaction(PPI)network was constructed and analyzed using the STRING online analysis platform.Uses the Database for Annotation,Visualization and Integrated Discovery(DAVID)to perform GO function enrichment analysis of targets and enrichment of KEGG pathways analysis.Results:A total of 33 potential active ingredients were screened from Aidi injection for treating hepatocellular carcinoma,including quercetin,kaempferol,beta-sitosterol,isorhamnetin and other important active ingredients.There are 106 potential targets for active ingredient action,6,677 disease-related targets,and 89 drug-disease common targets.Through the network diagram,it was found that the highest degree of target is PTGS1.In the PPI graph,a total of 87 nodes.Among them,the higher degree values include IL6,CASP3,VEGFA,MAPK8,JUN,EGFR,MYC,PTGS2 and FOS.A total of 60 related signal pathways were obtained by GO enrichment analysis.It mainly involves biological processes such as inhibiting abnormal proliferation and differentiation of hepatocellular carcinoma cells,inhibiting angiogenesis of hepatocellular carcinoma,regulating cell cycle and promoting apoptosis.KEGG pathway enrichment analysis screened a total of eight significantly different signal pathways.Among them,P53,VEGF,MAPK,Toll-like receptor,ErbB signaling pathways play an important role in treatment.Conclusion:This study initially revealed the potential mechanism of multi-component,multi-target and multi-pathway treatment of Aidi injection for hepatocellular carcinoma,and provided ideas for the subsequent verification of the molecular mechanism of Aidi injection for hepatocellular carcinoma.

Effects of Aidi injection on vinorelbine plus cisplatin chemotherapy for advanced non-small cell lung cancer

Objective： To evaluate the effects of Aidi injection on vinorelbine plus cisplatin （NP） chemotherapy for advanced non-small cell lung cancer （NSCLC）. Methods： Ninety eight patients with advanced NSCLC were randomized to receive either NP alone or NP plus Aidi injection every 3 weeks. The primary endpoint was overall survival; secondary endpoints included overall response rate, time to progression, and safety. Results： The median overall survival time was 11.6 months in NP plus Aidi-treated patients and 10.1 months in NP alone-treated ones, and 1- and 2-year survival rates were higher in the former （47% and 22%） than the latter （42% and 15%）. The overall response rates in Aidi injection plus NP-treated patients tended to be higher but not statistically significant compared with NP alone-treated ones. The occurrence rates of grades 3 or 4 toxicities, e.g. fatigue, nausea, vomiting, appetite loss, leucopenia, thrombocytopenia and anemia, were lower in Aidi injec- tion plus NP-treated patients than NP alone-treated ones, although not significantly different between them. Con^lusion：Aidi injection promotes NP chemotherapeutic effects, reduces the toxicities, and improves the patients＇ tolerance to chemotherapy as well. It may be an effective adjunct to chemotherapy in patients with NSCLC.

Effect of Aidi injection-assisted intravenous chemotherapy on serum tumor markers and peripheral blood immune molecules in patients with colon cancer

Objective:To discuss the effect of Aidi injection-assisted intravenous chemotherapy on serum tumor markers and peripheral blood immune molecules in patients with colon cancer. Methods: 92 patients with colon cancer who were hospitalized in Deyang People's Hospital in Sichuan Province between October 2013 and October 2016 were collected and divided into the control group (n=50) who received intravenous chemotherapy alone and the observation group (n=42) who received Aidi injection-assisted intravenous chemotherapy after the therapies were reviewed. The differences in serum tumor markers and peripheral blood immune molecule contents before and after treatment were compared between two groups of patients.Results:Before treatment, differences in serum tumor marker levels and peripheral blood immune molecule levels were not statistically significant between two groups of patients. After treatment, serum tumor markers CEA, CA199, CA50, PTN and CCSA-2 levels of observation group were lower than those of control group, peripheral blood Th1/Th2 cytokines IL-2 and IFN-γ levels were higher than those of control group while IL-4 and IL-10 levels were lower than those of control group, and peripheral blood Th17 cytokines IL-17A and IL-22 levels were lower than those of control group.Conclusion: Aidi injection-assisted intravenous chemotherapy can effectively reduce the serum tumor marker contents and optimize the immune molecule levels in patients with colon cancer.

Effect of Aidi injection combined with FOLFOX4 chemotherapy on tumor stem cell characteristics and antitumor immune response in patients with advanced colon cancer

Objective:To study the effect of Aidi injection combined with FOLFOX4 chemotherapy on tumor stem cell characteristics and antitumor immune response in patients with advanced colon cancer.Methods:Patients with advanced colon cancer who received chemotherapy in our hospital between May 2013 and June 2016 were selected and randomly divided into the combined chemotherapy group who received Aidi injection combined with FOLFOX4 chemotherapy and the FOLFOX4 group who received FOLFOX4 chemotherapy alone. After chemotherapy, the serum was collected to determine the levels of tumor markers, tumor lesions were collected to determine the expression of tumor stem cell markers and immune cell markers, and peripheral blood mononuclear cells were collected to determine the expression of immune cell markers.Results:After 2 and 4 cycles of treatment, serum CEA, CA199, CCSA-3 and CCSA-4 levels of combined chemotherapy group were significantly lower than those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 in peripheral blood mononuclear cells were significantly higher than those of FOLFOX4 group;after four cycles of chemotherapy, CD133, Musashi-1, Piwil2, Nanog and Sox-2 protein content in tumor lesions were significantly lower than those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 were significantly higher than those of FOLFOX4 group.Conclusion: Aidi injection combined with FOLFOX4 chemotherapy treatment of advanced colon cancer will help reduce the tumor load, inhibit tumor stem cell characteristics and enhance antitumor immune response.

Influence of Aidi injection combined with paclitaxel and platinum drugs on malignant molecule expression in malignant ascites of patients with advanced gastric cancer

Objective: To explore the influence of Aidi injection combined with paclitaxel and platinum drugs on malignant molecule expression in malignant ascites of patients with advanced gastric cancer. Methods: A total of 80 patients with advanced gastric cancer complicated by malignant ascites who were treated in the hospital between January 2015 and December 2016 were divided into control group and observation group by random number table, each with 40 cases. Control group were treated with paclitaxel and platinum drugs, and observation group were treated with Aidi injection combined with paclitaxel and platinum drugs. The differences in the malignant molecule expression in malignant ascites were compared between the two groups of patients before and after treatment. Results: Before treatment, the proliferation, invasion and autophagy gene expression in malignant ascites were not statistically different between the two groups of patients. 1 week after treatment, EZH2, I2PP2A, Gal-1, HPA-1, MTA1, TROP2, BNIP3 and LC3 mRNA expression in malignant ascites of both groups of patients were lower than those before treatment while PTPN13, TRIM28, SOX7, Syndecan-1 and Beclin1 mRNA expression were higher than those before treatment, and EZH2, I2PP2A, Gal-1, HPA-1, MTA1, TROP2, BNIP3 and LC3 mRNA expression in malignant ascites of observation group were lower than those of control group while PTPN13, TRIM28, SOX7, Syndecan-1 and Beclin1 mRNA expression were higher than those of control group. Conclusion: Aidi injection combined with paclitaxel and platinum drugs can effectively inhibit the gastric cancer cell proliferation and invasion, and regulate cell autophagy activity in the malignant ascites of patients with advanced gastric cancer.

喂线技术在ADI凸轮轴生产中的应用

ADI凸轮轴良好的耐磨性、强度受到铸造领域中人们的重视。为了更好地满足等温淬火球墨铸铁件生产工艺要求,以及形成从生产优质球铁凸轮轴到等温淬火的整个过程的成套技术,分别应用喂线法与冲入法生产优质球墨铸铁凸轮轴。对比结果表明:用喂线法生产的球铁凸轮轴球化率、石墨球的圆整度及大小和数量都优于冲入法,结果稳定,铸件亦有很好的力学性能。并在相同等温淬火工艺和等温淬火设备下,等温淬火以后喂线法试样的力学性能优于与冲入法。

覆砂铁型铸造工艺生产ADI摩擦斜楔

介绍了采用覆砂铁型铸造生产火车用摩擦斜楔ADI铸件的铸造工艺和热处理工艺。通过采用半封闭式浇注系统和过滤网挡渣;选用合理的炉料配比及喂丝球化处理工艺;采用盐浴等温淬火工艺,最终获得以贝氏体+残余奥氏体为基体的高强度、高硬度及高韧性的ADI铸件。

含奥沙利铂化疗方案联合艾迪注射液对晚期结直肠癌患者免疫功能及生活质量的影响

目的探讨含奥沙利铂化疗方案联合艾迪注射液对晚期结直肠癌(CRC)患者免疫功能及生活质量的影响。方法选取2021年3月至2023年3月江西中医药大学附属医院收治的93例CRC患者,按照随机数字表法分为对照组(47例)与试验组(46例)。对照组给予含奥沙利铂化疗方案治疗,在其基础上,试验组给予艾迪注射液治疗,比较两组临床疗效、免疫功能、肿瘤标志物水平与生活质量。结果试验组总有效率、CD4^(+)与CD3^(+)、生活质量总改善率均高于对照组,CD8^(+)、糖类抗原125(CA125)、癌胚抗原(CEA)与糖类抗原19-9(CA19-9)均低于对照组,差异有统计学意义(P<0.05)。结论含奥沙利铂化疗方案、艾迪注射液联合治疗晚期CRC疗效确切,可降低肿瘤标志物水平,增强免疫功能,提高生活质量。

艾迪注射液联合DP化疗方案对NSCLC血清肿瘤标志物水平的影响

目的探讨艾迪注射液结合多西他赛+顺铂(DP)化疗对非小细胞肺癌(NSCLC)患者血清肿瘤标志物水平的影响。方法选取2020年10月至2022年10月在本院收治的96例NSCLC患者,使用随机数字表法将其分为艾迪联合DP组和DP组各48例,并比较两组的疗效、血清肿瘤标志物水平以及不良反应的差异。结果艾迪联合DP组有效率41.67%,明显高于DP组(22.92%)(P<0.05)。治疗后,艾迪联合DP组和DP组的CEA和CYFRA21-1水平均显著降低(P<0.05),而艾迪联合DP组的降低幅度显著低于DP组(P<0.05)。此外,两组不良反应发生率也存在显著差异(P<0.05)。结论艾迪注射剂和DP化疗的联合治疗对NSCLC疗效显著,有助于降低肿瘤标志物水平并减少不良反应发生率。

艾迪注射液辅助SOX方案治疗晚期胃癌临床研究

目的:观察艾迪注射液辅助SOX方案治疗晚期胃癌的临床疗效。方法:选取64例晚期胃癌患者,按照奇偶数随机分为试验组和对照组,每组32例。对照组行SOX方案治疗,试验组在SOX方案基础上联用艾迪注射液治疗。21 d为1个疗程,2组均治疗6个疗程,随访18个月。比较2组临床疗效、肿瘤标志物[血清糖类抗原724(CA724)、糖类抗原125(CA125)、糖类抗原199(CA199)、癌胚抗原(CEA)]水平、症状积分、piper疲乏调查量表(PSR-R)评分、Karnofsky(KPS)评分、不良反应发生率、肿瘤进展时间(TTP)及中位生存时间(MST)。结果:治疗6个疗程后,试验组疾病控制率(DCR)为93.75%,疾病有效率(ORR)为68.75%,均高于对照组68.75%、40.63%,差异均有统计学意义(P<0.05);2组血清CA125、CA199、CA724、CEA水平均较治疗前降低,试验组血清CA125、CA199、CEA水平均低于对照组,差异均有统计学意义(P<0.05);2组血清CA724水平比较,差异无统计学意义(P>0.05)。2组症状积分、PSR-R评分均较治疗前降低,KPS评分均较治疗前升高,差异均有统计学意义(P<0.05);试验组症状积分及PSR-R评分均低于对照组,KPS评分高于对照组,差异均有统计学意义(P<0.05)。治疗6个疗程期间,除肝肾功能损害外,试验组血小板减少、血红蛋白减少、白细胞减少、周围神经毒性不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。随访18个月,试验组TTP和MST均长于对照组,差异均有统计学意义(P<0.05)。结论:艾迪注射液辅助SOX方案治疗晚期胃癌能够提升治疗效果,延长患者的生存期,降低不良反应发生率。

艾迪注射液辅助化疗治疗老年晚期非小细胞肺癌患者的疗效分析

目的探讨对老年晚期非小细胞肺癌患者给予艾迪注射液辅助化疗治疗的临床效果。方法62例老年晚期非小细胞肺癌患者,依据投掷硬币法分为参照组和研究组,各31例。参照组患者采用吉西他滨和顺铂(GP)化疗治疗,研究组患者在参照组基础上采用艾迪注射液治疗。比较两组患者治疗效果、免疫功能[CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)CD25^(+)调节性T细胞(Treg)]以及生存质量评分(生理层面、心理层面、社会层面、环境层面评分)。结果研究组客观有效率45.16%、疾病控制率87.10%均高于参照组的19.35%、54.84%(P<0.05)。治疗后,研究组CD3^(+)(55.65±7.86)%、CD4^(+)(36.29±5.49)%高于参照组的(50.16±8.42)%、(30.49±4.19)%,CD8^(+)(22.59±4.89)%、CD4^(+)CD25^(+)Treg(4.36±1.08)%低于参照组的(26.15±4.36)%、(8.15±1.39)%(P<0.05)。治疗后,研究组生理层面、心理层面、社会层面、环境层面评分分别为(70.33±3.12)、(71.44±3.25)、(71.64±5.22)、(71.87±4.25)分,高于参照组的(60.36±2.25)、(60.64±5.15)、(60.65±4.22)、(60.64±5.25)分(P<0.05)。结论临床对老年晚期非小细胞肺癌患者给予艾迪注射液辅助化疗治疗,可提升治疗效果以及生存质量,改善免疫功能,临床可推广应用。

基于网络药理学和细胞实验探讨艾迪注射液治疗卵巢癌的机制研究

目的利用网络药理学和细胞实验探讨艾迪注射液治疗卵巢癌的关键分子靶点及可能的作用机制。方法通过中药系统药理学数据库与分析平台(Troditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)数据库筛选艾迪注射液中中药的活性成分及作用靶点,并筛选卵巢癌异常表达的基因,取交集后获得艾迪注射液作用于卵巢癌的可能靶点。接着对可能靶点进行蛋白质互作网络分析、构建药物-化合物-靶点网络和富集分析。进一步筛选靶点,对与卵巢癌预后相关的关键基因进行实验验证,用50mg/ml艾迪注射液处理卵巢癌细胞后利用CCK-8实验观察细胞增殖能力,实时荧光定量聚合酶链反应技术检测核心靶基因的表达。结果筛选到艾迪注射液作用于卵巢癌的可能靶点共13个。这些靶点主要富集于细胞凋亡、铂耐药和白细胞介素-17等肿瘤发生、发展密切相关的信号通路。13个基因中,与卵巢癌预后相关的关键基因为细胞间紧密连接蛋白4(claudin 4,CLDN4)、分泌性白细胞蛋白酶抑制因子(secretory leukocyte peptidase inhibitor,SLPI)和杆状病毒IAP重复序列包含5(baculoviral IAP repeat containing 5,BIRC5)。细胞实验发现,艾迪注射液能显著抑制卵巢癌细胞增殖,促进卵巢癌保护性靶点BIRC5的表达,并显著下降卵巢癌危险因素CLDN4和SLPI的水平。结论艾迪注射液可能是通过影响CLDN4、SLPI、BIRC5这3个核心靶点的表达来实现多成分、多靶点、多途径的抗卵巢癌和联合化疗的增效减毒作用。

艾迪注射液联合mFOLFOX6方案对晚期结直肠癌化疗患者T淋巴细胞水平及化疗安全性的影响

目的:研究艾迪注射液+mFOLFOX6方案运用于晚期结直肠癌化疗中的价值。方法:选择2022年7月—2023年3月九江市第一人民医院纳入的90例晚期结直肠癌化疗患者,按随机数字表法分为两组,各45例。研究组接受艾迪注射液+mFOLFOX6方案,对照组采取mFOLFOX6方案。比较两组毒副反应、症候积分、T淋巴细胞、糖类抗原242(CA242)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、辅助型T细胞(Th)1、Th2、Th1/Th2、生活质量(QOL)。结果:研究组恶心呕吐、便秘、腹泻、骨髓抑制、外周神经毒性的发生率均低于对照组,差异均有统计学意义(P<0.05)。两组用药前的症候积分比较,差异均无统计学意义(P>0.05),研究组用药后的各项积分均较对照组更低,差异均有统计学意义(P<0.05)。两组用药前的T淋巴细胞水平比较,差异均无统计学意义(P>0.05),研究组用药后的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较对照组高,但CD8^(+)低于对照组,差异均有统计学意义(P<0.05)。两组用药前的肿瘤标志物比较,差异均无统计学意义(P>0.05),研究组用药后的CA242、CA19-9、CEA均较对照组更低,差异均有统计学意义(P<0.05)。两组用药前的QOL各项评分比较,差异均无统计学意义(P>0.05),研究组用药后的QOL各项评分均较对照组高,差异均有统计学意义(P<0.05)。两组用药前的免疫指标比较,差异均无统计学意义(P>0.05),研究组用药后的Th1、Th1/Th2均较对照组更低,但Th2高于对照组,差异均有统计学意义(P<0.05)。结论:艾迪注射液+mFOLFOX6方案应用于晚期结直肠癌患者的效果更为理想,可促进患者T淋巴细胞及肿瘤标志物水平改善,减轻患者症状,并调节免疫,提高生活质量,毒副反应较少,安全性更高。

艾迪注射液对宫颈癌细胞的放疗增敏性作用观察

目的 探讨艾迪注射液对宫颈癌细胞的放疗增敏性作用及其机制。方法 取宫颈癌SiHa细胞进行培养,随机分为空白对照组和艾迪注射液组,空白对照组加入细胞培养液100μL,艾迪注射液组加入10 mg/mL艾迪注射液100μL。培养24 h后,使用医用直线加速器对两组细胞进行放疗,分别给予0、2、4、6、8 Gy照射剂量。观察两组0 Gy时的克隆形成率(PE),根据PE计算两组2、4、6、8 Gy时的存活分数(SF),SF降低表示放疗敏感性增加。另取SiHa细胞分为空白对照组、放疗组、艾迪+放疗组,空白对照组加入细胞培养液100μL,放疗组加入100μL细胞培养液后给予10 Gy照射剂量放疗,艾迪+放疗组加入10 mg/mL艾迪注射液100μL后给予10 Gy照射剂量放疗。采用流式细胞术观察三组细胞凋亡情况,实时定量PCR法检测细胞Bcl-2 mRNA表达。结果 艾迪注射液组照射剂量2、4、6、8 Gy时的SF较空白对照组降低(P=0.002)。放疗组细胞凋亡率高于空白对照组,艾迪+放疗组细胞凋亡率高于放疗组(P均<0.01)。放疗组细胞Bcl-2 mRNA表达低于空白对照组,艾迪+放疗组Bcl-2 mRNA表达低于放疗组(P均<0.01)。结论 艾迪注射液可增加宫颈癌细胞的放疗敏感性,其机制可能是通过抑制Bcl-2表达来促进细胞凋亡。

基于网络药理学和分子对接探讨艾迪注射液治疗结直肠癌作用机制研究

目的运用网络药理学及分子对接技术探讨艾迪注射液治疗结直肠癌(CRC)的有效活性成分及潜在作用机制。方法从TCMSP、TCM-ID数据库及文献检索中提取艾迪注射液的主要活性物质,并使用SwissTargetPrediction数据库进一步确定其可能的作用靶标;从GeneCards、OMIM、DisGeNET数据库中获取CRC疾病基因靶点。运用STRING数据库及Cytoscape 3.9.1制作“药物活性成分靶点”及PPI网络图。运用Metascape数据库对交集靶点进行GO和KEGG富集分析。运用分子对接验证关键成分与疾病分子间的联系。结果共筛选出39个艾迪注射液有效成分,684个疾病分子,与CRC共有169个靶点。GO功能富集结果显示有188个分子功能、108个细胞组成、1845个生物过程。KEGG分析得到200条通路途径。分子对接结果显示,艾迪注射液核心成分华良姜素、山柰酚、槲皮素等,与疾病分子TP53、BCL2、AKT1、CCND1、CASP3对接良好。结论艾迪注射液可能通过华良姜素、山柰酚、槲皮素等活性成分调节TP53、BCL2、AKT1、CCND1、CASP3等核心靶点从而治疗CRC。

艾迪注射液治疗晚期胃癌的预后及与外周血lncRNA ZNF667⁃AS1及miR⁃126表达与的关系

目的探讨艾迪注射液治疗晚期胃癌的预后及与外周血lncRNA ZNF667⁃AS1及miR⁃126表达的关系。方法收集2022年1月至2023年3月间于安徽省颍上县人民医院接受治疗的晚期胃癌患者60例,所有患者接受放化疗配合艾迪注射液治疗,随访1年,存活病例纳入预后良好组(n=44),死亡病例纳入预后不良组(n=16)。比较两组患者一般资料及外周血lncRNA ZNF667⁃AS1、miR⁃126表达水平,分析外周血lncRNA ZNF667⁃AS1、miR⁃126表达水平与晚期胃癌患者艾迪注射液治疗预后的关系,评估外周血lncRNA ZNF667⁃AS1、miR⁃126表达水平对晚期胃癌患者艾迪注射液治疗预后的预测价值。结果经随访发现,预后不良16例、占26.67%;预后良好44例、占73.33%。预后不良组外周血lncRNA ZNF667⁃AS1、miR⁃126表达水平均低于预后良好组,差异有统计学意义(P<0.05)。Logistic回归分析结果显示,外周血lncRNA ZNF667⁃AS1、miR⁃126异常低表达均是晚期胃癌患者预后不良的独立危险因素(OR>1,P<0.05);ROC曲线图显示,外周血lncRNA ZNF667⁃AS1+miR⁃126预测晚期胃癌患者艾迪注射液治疗预后的AUC为0.924,灵敏度、特异度分别为90.20%、83.60%。结论外周血lncRNA ZNF667⁃AS1、miR⁃126低表达与晚期胃癌患者艾迪注射液治疗预后不良有关。

介入化疗栓塞联合中成药艾迪注射液在中晚期胰腺癌治疗中的应用价值

目的分析评价介入化疗栓塞联合中成药艾迪注射液在提高中晚期胰腺癌患者生存率中的应用价值。方法选取2020年03月-2024年02月我院符合入选标准且同意参与研究的患者76例,随机分配到两组,实验组接受介入化疗栓塞联合中成药艾迪注射液治疗,对照组接受常规化疗;对比分析两组间治疗后CA199指标改善及无进展生存率间的差异。结果介入化疗栓塞联合中成药艾迪注射液治疗对CA199指标的改善效果显著且无进展生存率与单纯化疗相比具有明显优势,差异具有统计学意义(P<0.05)。结论介入化疗栓塞联合中成药艾迪注射液在中晚期胰腺癌患者中显示出明显的临床效果,可以推广应用。

艾迪注射液联合XELOX化疗方案治疗晚期结直肠癌患者的效果

目的:观察艾迪注射液联合XELOX(卡培他滨+奥沙利铂)化疗方案治疗晚期结直肠癌患者的效果。方法:选取2022年1月至2023年6月该院收治的76例晚期结直肠癌患者进行前瞻性研究,按随机数字表法将其分为对照组与研究组各38例。对照组采用XELOX化疗方案治疗,研究组在对照组基础上联合艾迪注射液治疗。比较两组临床疗效,治疗前后卡氏功能状态(KPS)评分、肿瘤标志物[糖类抗原72-4(CA72-4)、癌胚抗原(CEA)、糖类抗原242(CA242)]水平,以及不良反应发生率。结果:研究组疾病控制率为63.16%(24/38),高于对照组的39.47%(15/38),差异有统计学意义(P<0.05);治疗后,两组KPS评分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组CA72-4、CEA、CA242水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为18.42%,低于对照组的42.11%,差异有统计学意义(P<0.05)。结论:艾迪注射液联合XELOX化疗方案治疗晚期结直肠癌患者可提高疾病控制率和KPS评分,降低肿瘤标志物水平和不良反应发生率,其效果优于单纯XELOX化疗方案治疗。

艾迪注射液对肝癌部分切除患者术后肝功能的影响

目的探讨艾迪注射液用于肝癌部分切除患者术后的临床效果。方法90例肝癌部分切除手术患者随机分为两组。术后,对照组给予还原型谷胱甘肽治疗,观察组在对照组基础上给予艾迪注射液治疗。比较两组的免疫功能、肝功能及肿瘤标志物。结果治疗后,观察组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均显著高于对照组,CD8^(+)水平显著低于对照组(P<0.05)。治疗后,观察组的TBIL、AST、ALT水平均显著低于对照组(P<0.05)。治疗后,观察组的AFP、CEA水平均显著低于对照组(P<0.05)。结论艾迪注射液用于肝癌部分切除术后患者,可有效改善其免疫功能及肝功能,降低肿瘤标志物水平。

艾迪注射液联合TC化疗方案治疗子宫内膜癌患者的效果

目的:观察艾迪注射液联合卡铂^(+)紫杉醇(TC)化疗方案治疗子宫内膜癌(EC)患者的效果。方法:回顾性收集2021年6月至2023年6月该院收治的68例EC患者的临床资料,按治疗方案不同将其分为对照组与观察组各34例。对照组采用TC化疗方案治疗,观察组在对照组基础上联合艾迪注射液治疗。比较两组疾病控制率,治疗前后T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平、疾病相关指标[血清高半胱氨酸蛋白61(Cyr61)、内脂素(Visfatin)]水平,以及不良反应发生率。结果:观察组疾病控制率为94.12%,高于对照组的76.47%,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但观察组高于对照组,差异有统计学意义(P<0.05);治疗后两组Cyr61、Visfatin水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组骨髓抑制、脱发、肝肾功能异常、消化道反应等不良反应发生率与对照组比较,差异均无统计学意义(P>0.05)。结论:艾迪注射液联合TC化疗方案治疗EC患者可提高疾病控制率和T细胞亚群指标水平,以及降低疾病相关指标水平的效果优于单纯TC化疗方案治疗。